MS Speaks

Multiple Sclerosis => MS - RESEARCH AND NEWS => Topic started by: agate on April 21, 2016, 04:10:22 pm

Title: (AAN abst.) Smoking cessation decelerates brain volume loss in MS patients
Post by: agate on April 21, 2016, 04:10:22 pm
Presented at the annual AAN conference in Vancouver, BC, this month:

Quote
S37.003 - Smoking Cessation Decelerates Brain Volume Loss in Patients with Multiple Sclerosis

 April 20, 2016, 7:00 AM - 7:15 AM
   
Authors


Navid Seraji-Bozorgzad, Fen Bao, Sara Razmjou, Christina Caon, Alexandros Tselis, Carla Santiago Martinez, Imad Zak, Evanthia Bernitsas, Omar Khan
Detroit, MI, USA

Disclosures


 N. Seraji-Bozorgzad: None. F. Bao: None. S. Razmjou: None. C. Caon: ; Speaker for branded and un-branded lectures. Paid to be advisor at advisory boards and consultant meetings. A. Tselis: ; Dr. Tselis has recieved research support from Teva Neuroscience and Biogenic Idec.. C. Santiago Martinez: None. I. Zak: None. E. Bernitsas: ; Biogen Idec, Novartis, Teva Neuroscience. O. Khan: ; Consulting fees from: Biogen Idec, Genzyme, Novartis; Speakers Bureau for Teva, Novartis, Biogen Idec, Received research funding from NIH, NINDS, NMSS, Teva, Biogen Idec, Genzyme, Roche, and Novartis.

Objective:

To study the effect of cessation of smoking on brain volume loss in MS.

Background:

Smoking has been shown to increase rate of brain atrophy in MS. However, no study has evaluated the effect of smoking cessation on brain volume in MS.

Methods:

We examined the records of relapsing MS patients on whom smoking information was available. Brain MRI scans done (3T) obtained for clinical monitoring, were utilized to measure the percent change in brain volume (SIENA).

Results:

254 relapsing MS patients were included in the study. All patients had smoked cigarettes for > 5 years. Smoking or cessation of smoking was self reported and documented in medical charts. The mean age was 32.8 years, T2 lesion load 8.2 ml, CEL number 0.7, and baseline brain volume was 1521 ml.

Of 254, 148 continued to smoke while 106 stopped smoking. There were no significant differences between the two groups at baseline. PBVC measured by SIENA was divided into two phases. Phase I was from baseline scan to year 4 scan during which both groups continued to smoke. Phase II was from year 4 to year 6, during which one group continued to smoke while the other group stopped smoking. The annual PBVC in the group that continued smoking was -0.54 in phase I and -0.51 in phase II (p=0.036). The annual PBVC in the group who stopped smoking was -0.55 in phase I and -0.38 in phase II (p<0.0001).

Compared to patients who continued to smoke, patients who stopped smoking demonstrated significant decline in the rate of brain volume loss (PBVC: -0.38 vs -0.51, p<0.0001).

Conclusions:

To the best of our knowledge, this is the first study indicating that cessation of smoking decelerates brain volume loss in MS patients. Cessation of smoking should be counseled to patients with MS